JP2017500338A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500338A5 JP2017500338A5 JP2016541373A JP2016541373A JP2017500338A5 JP 2017500338 A5 JP2017500338 A5 JP 2017500338A5 JP 2016541373 A JP2016541373 A JP 2016541373A JP 2016541373 A JP2016541373 A JP 2016541373A JP 2017500338 A5 JP2017500338 A5 JP 2017500338A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- formula
- methyl
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322755.8A GB201322755D0 (en) | 2013-12-20 | 2013-12-20 | Bicyclic heterocycle compounds and their uses in therapy |
| GB1322755.8 | 2013-12-20 | ||
| GB201406986A GB201406986D0 (en) | 2014-04-17 | 2014-04-17 | Bicyclic heterocycle compounds and their uses in therapy |
| GB1406986.8 | 2014-04-17 | ||
| PCT/GB2014/053778 WO2015092420A1 (en) | 2013-12-20 | 2014-12-19 | Bicyclic heterocycle compounds and their uses in therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019005876A Division JP6735369B2 (ja) | 2013-12-20 | 2019-01-17 | 二環式複素環化合物および治療におけるそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500338A JP2017500338A (ja) | 2017-01-05 |
| JP2017500338A5 true JP2017500338A5 (enExample) | 2018-02-01 |
| JP6470756B2 JP6470756B2 (ja) | 2019-02-13 |
Family
ID=52134239
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541373A Active JP6470756B2 (ja) | 2013-12-20 | 2014-12-19 | 二環式複素環化合物および治療におけるそれらの使用 |
| JP2019005876A Active JP6735369B2 (ja) | 2013-12-20 | 2019-01-17 | 二環式複素環化合物および治療におけるそれらの使用 |
| JP2020119260A Active JP7110279B2 (ja) | 2013-12-20 | 2020-07-10 | 二環式複素環化合物および治療におけるそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019005876A Active JP6735369B2 (ja) | 2013-12-20 | 2019-01-17 | 二環式複素環化合物および治療におけるそれらの使用 |
| JP2020119260A Active JP7110279B2 (ja) | 2013-12-20 | 2020-07-10 | 二環式複素環化合物および治療におけるそれらの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9783538B2 (enExample) |
| EP (2) | EP3083616B1 (enExample) |
| JP (3) | JP6470756B2 (enExample) |
| KR (1) | KR102408262B1 (enExample) |
| CN (3) | CN115368356B (enExample) |
| AU (2) | AU2014369446C1 (enExample) |
| BR (2) | BR112016014561B1 (enExample) |
| CA (1) | CA2933939C (enExample) |
| CY (1) | CY1124436T1 (enExample) |
| DK (1) | DK3083616T3 (enExample) |
| ES (1) | ES2883289T3 (enExample) |
| HR (1) | HRP20211406T1 (enExample) |
| HU (1) | HUE056297T2 (enExample) |
| IL (1) | IL246239B (enExample) |
| LT (1) | LT3083616T (enExample) |
| MX (1) | MX380469B (enExample) |
| MY (2) | MY186311A (enExample) |
| NZ (2) | NZ719905A (enExample) |
| PH (1) | PH12016501139A1 (enExample) |
| PL (1) | PL3083616T3 (enExample) |
| PT (1) | PT3083616T (enExample) |
| RS (1) | RS62301B1 (enExample) |
| RU (1) | RU2696310C1 (enExample) |
| SA (1) | SA516371360B1 (enExample) |
| SG (2) | SG10201808102WA (enExample) |
| SI (1) | SI3083616T1 (enExample) |
| SM (1) | SMT202100497T1 (enExample) |
| TW (1) | TWI649319B (enExample) |
| WO (1) | WO2015092420A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201106814D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compounds |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2017091762A1 (en) | 2015-11-25 | 2017-06-01 | Io Therapeutics, Inc. | Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer |
| EP3419643A4 (en) * | 2016-02-24 | 2020-04-01 | Children's Hospital of Eastern Ontario Research Institute Inc. | SMC COMBINATION THERAPY FOR TREATING CANCER |
| AU2017253560B2 (en) | 2016-04-20 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising RIPK2 inhibitors |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CA3026563C (en) | 2016-06-10 | 2023-11-28 | Io Therapeutics, Inc. | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| US20210154184A1 (en) | 2017-07-12 | 2021-05-27 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| CA3069672A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy |
| CA3073953A1 (en) | 2017-08-31 | 2019-03-07 | Io Therapeutics, Inc. | Rar selective agonists in combination with immune modulators for cancer immunotherapy |
| US20210361774A1 (en) | 2018-10-16 | 2021-11-25 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 |
| EP3911316A1 (en) | 2019-01-17 | 2021-11-24 | Debiopharm International SA | Combination product for the treatment of cancer |
| ES3055186T3 (en) | 2019-04-04 | 2026-02-10 | Dana Farber Cancer Inst Inc | Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer |
| TW202120486A (zh) * | 2019-08-09 | 2021-06-01 | 英商阿帝歐斯製藥有限公司 | 新穎化合物 |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| AU2020356356A1 (en) | 2019-09-25 | 2022-05-12 | Debiopharm International S.A. | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| JP7690493B2 (ja) * | 2020-05-04 | 2025-06-10 | 大鵬薬品工業株式会社 | Ｉａｐアンタゴニスト化合物及びその中間体、並びにそれを合成する方法 |
| WO2021225956A1 (en) * | 2020-05-04 | 2021-11-11 | Astex Pharmaceuticals, Inc. | Methods for synthesizing anhydrous lactic acid |
| CA3174831A1 (en) | 2020-06-04 | 2021-12-09 | Beigene, Ltd. | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as iap antagonists |
| BR112023002457A2 (pt) * | 2020-08-12 | 2023-05-02 | Archer Daniels Midland Co | Processo para purificar uma composição bruta compreendendo ácido 2,5-furanodicarboxílico, éster de dimetila (fdme) |
| JP2023539867A (ja) | 2020-08-27 | 2023-09-20 | 大塚製薬株式会社 | Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー |
| AU2021342287A1 (en) * | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| WO2022183006A1 (en) | 2021-02-25 | 2022-09-01 | Mayo Foundation For Medical Education And Research | Compounds for programmable protein degradation and methods of use for the disease treatment |
| GB202103080D0 (en) * | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| WO2023022235A1 (ja) | 2021-08-20 | 2023-02-23 | 大塚製薬株式会社 | 組み合わせ医薬 |
| KR20240132251A (ko) * | 2021-10-22 | 2024-09-03 | 유니버시티 오브 휴스턴 시스템 | 상피 조직의 만성 염증성 손상, 화생, 이형성증 및 암을 치료하기 위한 방법 및 조성물 |
| CN118139620A (zh) * | 2021-11-05 | 2024-06-04 | 上海海和药物研究开发股份有限公司 | 一种固体分散体、其制备方法及包含其的固体制剂 |
| JP2025508016A (ja) | 2022-03-04 | 2025-03-21 | 大鵬薬品工業株式会社 | Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法 |
| EP4529455A1 (en) | 2022-05-23 | 2025-04-02 | Inhibrx Biosciences, Inc. | Dr5 agonist and iap antagonist combination therapy |
| JP2025529240A (ja) | 2022-08-31 | 2025-09-04 | 大鵬薬品工業株式会社 | トリナパント、セダズリジン及びデシタビンによるｔ細胞リンパ腫の治療のための併用療法 |
| CN118027138A (zh) * | 2022-11-07 | 2024-05-14 | 南京中澳转化医学研究院有限公司 | 吡啶酮类化合物及其制备方法、药物组合物和应用 |
| CN116375700B (zh) * | 2023-01-10 | 2024-12-17 | 中国科学院成都生物研究所 | 一种4-氮杂吲哚啉类化合物及其合成方法与应用 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| EP4753679A1 (en) | 2023-07-31 | 2026-06-10 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical compositions including tolinapant and packaging |
| WO2025235719A1 (en) * | 2024-05-08 | 2025-11-13 | Viiv Healthcare Company | Dimeric smac mimetics useful in hiv therapy |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080330A (en) | 1975-06-23 | 1978-03-21 | Delmar Chemicals Limited | Phenylindolines and process for their production |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| DE3822792C2 (de) | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| TW218875B (enExample) | 1992-03-09 | 1994-01-11 | Takeda Pharm Industry Co Ltd | |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| DK0778277T3 (da) | 1995-12-08 | 2003-10-27 | Pfizer | Substituerede heterocycliske derivater som CRF antagonister |
| ES2186874T3 (es) | 1996-02-22 | 2003-05-16 | Bristol Myers Squibb Pharma Co | Analogos de m-amidinofenilo como inhibidores del factor xa. |
| EP0944388A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| JP2000513375A (ja) | 1996-06-28 | 2000-10-10 | メルク エンド カンパニー インコーポレーテッド | フィブリノーゲンレセプター拮抗薬プロドラッグ |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1998050346A2 (en) | 1997-04-18 | 1998-11-12 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
| AU732863B2 (en) | 1997-04-18 | 2001-05-03 | Smithkline Beecham Plc | Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity |
| US6084098A (en) | 1999-02-26 | 2000-07-04 | Neurogen Corporation | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands |
| HUP0100926A3 (en) | 1998-02-26 | 2003-03-28 | Neurogen Corp Branford | Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 receptor antagonists |
| KR100672186B1 (ko) | 1998-03-31 | 2007-01-19 | 아카디아 파마슈티칼스 인코포레이티드 | 무스카린 수용체에 대해 활성을 갖는 화합물 |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| PT1114028E (pt) | 1998-08-26 | 2007-02-28 | Aventis Pharma Ltd | Aza-biciclos moduladores da inibição da adesão celular |
| GB9905010D0 (en) | 1999-03-04 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| AU3555200A (en) | 1999-03-17 | 2000-10-04 | F. Hoffmann-La Roche Ag | Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators |
| GB9929552D0 (en) | 1999-12-14 | 2000-02-09 | Proteus Molecular Design | Compounds |
| WO2001012600A1 (en) | 1999-08-12 | 2001-02-22 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| AU6715200A (en) | 1999-09-04 | 2001-04-10 | Astrazeneca Ab | Amides as inhibitors for pyruvate dehydrogenase |
| GB0031088D0 (en) | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
| US20040180925A1 (en) | 2000-12-27 | 2004-09-16 | Kenji Matsuno | Dipeptidylpeptidase-IV inhibitor |
| AU2002303264A1 (en) | 2001-04-09 | 2002-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic inhibitors of factor xa |
| JP2004534017A (ja) | 2001-04-27 | 2004-11-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｂａｃｅのインヒビター |
| US20050245537A1 (en) | 2002-04-24 | 2005-11-03 | Noboru Tsuchimori | Use of compounds having ccr antagonism |
| TW200402417A (en) | 2002-06-21 | 2004-02-16 | Akzo Nobel Nv | 1-[(Indol-3-yl)carbonyl]piperazine derivatives |
| CN100516040C (zh) | 2003-03-07 | 2009-07-22 | 安斯泰来制药有限公司 | 具有2,6-二取代苯乙烯基的含氮杂环衍生物 |
| GB0307891D0 (en) | 2003-04-04 | 2003-05-14 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| US7514438B2 (en) | 2003-08-13 | 2009-04-07 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
| TW200524887A (en) | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
| PL2253614T3 (pl) | 2004-04-07 | 2013-03-29 | Novartis Ag | Inhibitory IAP |
| KR100926203B1 (ko) | 2004-07-02 | 2009-11-09 | 제넨테크, 인크. | Ｉａｐ의 억제제 |
| WO2006010118A2 (en) | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| WO2006032987A1 (en) | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Indoline compounds and their use in the treatment of arteriosclerosis |
| MX2007007195A (es) | 2004-12-20 | 2007-10-08 | Genentech Inc | Inhibidores de pirrolidina de iap. |
| EA012810B1 (ru) | 2005-02-25 | 2009-12-30 | Тетралоджик Фармасеутикалс | Димерные ингибиторы ингибиторов белков апоптоза (iap) |
| BRPI0618523A2 (pt) | 2005-11-11 | 2011-09-06 | Hoffmann La Roche | compostos de aminas cìclicas fundidas carbocìclicas, composições farmacêuticas e usos dos mesmos |
| WO2007106192A2 (en) | 2005-12-19 | 2007-09-20 | Genentech, Inc. | Inhibitors of iap |
| WO2007073405A1 (en) | 2005-12-21 | 2007-06-28 | Decode Genetics Ehf | N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation |
| FR2896504B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| GB0602335D0 (en) | 2006-02-07 | 2006-03-15 | Remynd Nv | Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases |
| JP2009534456A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| JP5452223B2 (ja) | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ阻害剤 |
| AU2007307763A1 (en) | 2006-10-12 | 2008-04-17 | Novartis Ag | Pyrrolydine derivatives as IAP inhibitors |
| CA2670726A1 (en) | 2006-12-07 | 2008-06-19 | Novartis Ag | 6-oxo-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases |
| AU2008223348A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| WO2008116107A2 (en) | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| EP2188292B1 (en) | 2007-08-08 | 2013-05-29 | GlaxoSmithKline Intellectual Property Development Limited | 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer |
| WO2009067233A1 (en) | 2007-11-20 | 2009-05-28 | Millennium Pharmaceuticals, Inc. | Beta carbolines and uses thereof |
| MX2010007948A (es) | 2008-01-24 | 2010-10-04 | Tetralogic Pharm Corp | Inhibidores de proteinas de apoptosis. |
| WO2009147476A1 (en) | 2008-06-02 | 2009-12-10 | Matrix Laboratories Ltd. | Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
| SG174146A1 (en) | 2009-02-27 | 2011-10-28 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
| WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
| SG175877A1 (en) | 2009-05-04 | 2011-12-29 | Plexxikon Inc | Compounds and methods for inhibition of renin, and indications therefor |
| CN102458116B (zh) | 2009-05-28 | 2014-12-31 | 泰特拉洛吉克药业公司 | Iap抑制剂 |
| UY33794A (es) * | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| GB201106814D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compounds |
| WO2013052110A1 (en) | 2011-10-03 | 2013-04-11 | The Trustees Of Columbia University In The City Of New York | Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| JP6232384B2 (ja) | 2012-01-06 | 2017-11-15 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
| GB201218864D0 (en) * | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| JP6510539B2 (ja) | 2014-01-09 | 2019-05-08 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン | 置換ベンゾオキサジン及び関連化合物 |
| JP7690493B2 (ja) | 2020-05-04 | 2025-06-10 | 大鵬薬品工業株式会社 | Ｉａｐアンタゴニスト化合物及びその中間体、並びにそれを合成する方法 |
| WO2021225956A1 (en) | 2020-05-04 | 2021-11-11 | Astex Pharmaceuticals, Inc. | Methods for synthesizing anhydrous lactic acid |
| JP2025508016A (ja) | 2022-03-04 | 2025-03-21 | 大鵬薬品工業株式会社 | Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法 |
| JP2025529240A (ja) | 2022-08-31 | 2025-09-04 | 大鵬薬品工業株式会社 | トリナパント、セダズリジン及びデシタビンによるｔ細胞リンパ腫の治療のための併用療法 |
-
2014
- 2014-12-19 CN CN202210613741.1A patent/CN115368356B/zh active Active
- 2014-12-19 SI SI201431877T patent/SI3083616T1/sl unknown
- 2014-12-19 NZ NZ71990514A patent/NZ719905A/en unknown
- 2014-12-19 HU HUE14815838A patent/HUE056297T2/hu unknown
- 2014-12-19 MX MX2016008131A patent/MX380469B/es unknown
- 2014-12-19 DK DK14815838.9T patent/DK3083616T3/da active
- 2014-12-19 BR BR112016014561-5A patent/BR112016014561B1/pt active IP Right Grant
- 2014-12-19 MY MYPI2016701668A patent/MY186311A/en unknown
- 2014-12-19 US US15/105,360 patent/US9783538B2/en active Active
- 2014-12-19 RU RU2016129472A patent/RU2696310C1/ru active
- 2014-12-19 BR BR122022015241-4A patent/BR122022015241B1/pt active IP Right Grant
- 2014-12-19 EP EP14815838.9A patent/EP3083616B1/en active Active
- 2014-12-19 SM SM20210497T patent/SMT202100497T1/it unknown
- 2014-12-19 HR HRP20211406TT patent/HRP20211406T1/hr unknown
- 2014-12-19 LT LTEPPCT/GB2014/053778T patent/LT3083616T/lt unknown
- 2014-12-19 CN CN201480069940.4A patent/CN105829310B/zh active Active
- 2014-12-19 NZ NZ758528A patent/NZ758528A/en unknown
- 2014-12-19 SG SG10201808102WA patent/SG10201808102WA/en unknown
- 2014-12-19 ES ES14815838T patent/ES2883289T3/es active Active
- 2014-12-19 EP EP19219371.2A patent/EP3686200A3/en active Pending
- 2014-12-19 KR KR1020167019182A patent/KR102408262B1/ko active Active
- 2014-12-19 RS RS20211096A patent/RS62301B1/sr unknown
- 2014-12-19 WO PCT/GB2014/053778 patent/WO2015092420A1/en not_active Ceased
- 2014-12-19 JP JP2016541373A patent/JP6470756B2/ja active Active
- 2014-12-19 CN CN201811129977.8A patent/CN109336883B/zh active Active
- 2014-12-19 CA CA2933939A patent/CA2933939C/en active Active
- 2014-12-19 MY MYPI2020002540A patent/MY193649A/en unknown
- 2014-12-19 AU AU2014369446A patent/AU2014369446C1/en active Active
- 2014-12-19 TW TW103144450A patent/TWI649319B/zh active
- 2014-12-19 PL PL14815838T patent/PL3083616T3/pl unknown
- 2014-12-19 PT PT148158389T patent/PT3083616T/pt unknown
- 2014-12-19 SG SG11201604795RA patent/SG11201604795RA/en unknown
-
2016
- 2016-06-13 PH PH12016501139A patent/PH12016501139A1/en unknown
- 2016-06-15 IL IL246239A patent/IL246239B/en active IP Right Grant
- 2016-06-19 SA SA516371360A patent/SA516371360B1/ar unknown
-
2017
- 2017-08-11 US US15/675,052 patent/US10618895B2/en active Active
-
2019
- 2019-01-17 JP JP2019005876A patent/JP6735369B2/ja active Active
- 2019-02-07 AU AU2019200840A patent/AU2019200840C1/en active Active
-
2020
- 2020-02-19 US US16/795,117 patent/US11225476B2/en active Active
- 2020-07-10 JP JP2020119260A patent/JP7110279B2/ja active Active
-
2021
- 2021-08-12 CY CY20211100729T patent/CY1124436T1/el unknown
- 2021-12-07 US US17/643,083 patent/US11643410B2/en active Active
-
2022
- 2022-12-21 US US18/069,571 patent/US12202828B2/en active Active
-
2024
- 2024-12-09 US US18/973,574 patent/US20250296930A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211406T1 (hr) | Biciklični heterociklični spojevi i njihove uporabe u liječenju | |
| ES2923875T3 (es) | Moduladores de la vía integrada del estrés | |
| CN113015724B (zh) | Kras g12c抑制剂化合物的关键中间体的改善合成 | |
| RU2702906C2 (ru) | Птеридины в качестве fgfr ингибиторов | |
| AU2014351413B2 (en) | Pyrrolopyrrolone derivatives and their use as BET inhibitors | |
| AU2006331912B2 (en) | Triazolopyridazines as tyrosine kinase modulators | |
| RU2602233C2 (ru) | Замещенные бензопиразиновые производные в качестве ингибиторов fgfr-киназ для лечения раковых заболеваний | |
| JP7158286B2 (ja) | ＰＩ３Ｋβ阻害剤としてのアザベンゾイミダゾール誘導体 | |
| JP2021020948A (ja) | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 | |
| KR20180094976A (ko) | Tank-결합 키나제 억제제 화합물 | |
| BR112020015056A2 (pt) | Moduladores de receptor de quimiocina e usos dos mesmos | |
| CA3110502A1 (en) | Pyrazolo[3,4-b]pyridine compounds as inhibitors of tam and met kinases | |
| ES2504977T3 (es) | Derivados hetero-bicíclicos como inhibidores del VHC | |
| JP2008505167A5 (enExample) | ||
| EP2203442B1 (en) | Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | |
| JP7244504B2 (ja) | ＰＩ３Ｋ－γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 | |
| PE20090506A1 (es) | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4 | |
| ES2811845T3 (es) | Heterociclos tricíclicos para el tratamiento del cáncer | |
| TW201202222A (en) | Inhibitors of HCV NS5A | |
| JP2015506985A5 (enExample) | ||
| US20190135772A1 (en) | Modulators of the integrated stress pathway | |
| Xun et al. | Small-molecule CSF1R inhibitors as anticancer agents | |
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| JP2013512268A5 (enExample) | ||
| JP2017516775A5 (enExample) |